文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

高流量鼻导管与持续气道正压通气在儿科重症监护中无创呼吸支持的性价比

Cost-effectiveness of high flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care.
PubMed 文献 · Crit Care · 2024-11-25
一句话结论FIRST-ABC试验成本效果分析显示,儿科重症监护中HFNC较CPAP平均费用更低且总体相对具有成本效果,但统计学不确定性大。

本研究基于FIRST-ABC两项随机对照试验数据,评估儿科重症监护中高流量鼻导管(HFNC)与持续气道正压通气(CPAP)的成本效果。分析纳入全因死亡率、健康相关生活质量(采用年龄适配的儿科生活质量通用核心量表,并映射为Child Health Utility 9D指数评分)和6个月内的费用,估算质量调整生命年(QALYs)。结果显示两组6个月增量QALYs相似;降阶梯RCT增量成本为-£4565(95%CI -£11,499至£2368),升阶梯RCT为-£5702(95%CI -£11,328至-£75);增量净效益分别为£4388(95%CI -£2551至£11,327)和£5628(95%CI -£8至£11,264)。成本效果结果存在相当大的不确定性,但在多数预设亚组中结果相似,且基础病例结果对替代假设稳健。

要点

  • 在升阶梯RCT(急性病患儿)中,HFNC较CPAP的6个月增量成本为-£5702(95%CI -£11,328至-£75),增量净效益为£5628(95%CI -£8至£11,264)。
  • 在降阶梯RCT(拔管后患儿)中,HFNC较CPAP的6个月增量成本为-£4565(95%CI -£11,499至£2368),增量净效益为£4388(95%CI -£2551至£11,327)。
  • 两项RCT中,HFNC与CPAP组6个月增量QALYs相似。
  • 成本效果结果存在相当大的统计不确定性,但在多数预设亚组中结果相似,且基础病例结果对替代假设稳健。
  • 临床有效性方面,升阶梯RCT中HFNC不劣于CPAP,而降阶梯RCT中HFNC未达到非劣效标准。

适用人群与场景

  • 儿科重症监护病房中需要无创呼吸支持的危重患儿,包括急性病患儿(升阶梯RCT)和拔管后患儿(降阶梯RCT)。

研究设计与关键结果

  • 研究类型:基于FIRST-ABC两项随机对照试验数据的成本效果分析。
  • 人群:儿科重症监护中需要无创呼吸支持的危重患儿,分为急性病患儿(升阶梯RCT)和拔管后患儿(降阶梯RCT)。
  • 干预与对照:HFNC vs CPAP。
  • 主要终点:6个月增量QALYs在两项RCT中两组相似。
  • 关键结果:降阶梯RCT增量成本为-£4565(95%CI -£11,499至£2368),升阶梯RCT为-£5702(95%CI -£11,328至-£75)。
  • 增量净效益:降阶梯RCT为£4388(95%CI -£2551至£11,327),升阶梯RCT为£5628(95%CI -£8至£11,264)。
  • 成本效果结果存在相当大的不确定性;多数预设亚组结果相似,基础病例结果对替代假设稳健。

证据类型、等级与局限

  • 证据类型:基于两项随机对照试验(FIRST-ABC)的成本效果分析。
  • 局限:原文报告成本效果结果存在相当大的统计不确定性;降阶梯RCT增量成本95%CI跨0,升阶梯RCT增量净效益95%CI下限接近0。

对床旁实践的改变

  • 作者认为,对于儿科重症监护中需要无创呼吸支持的危重患儿,HFNC相比CPAP可降低平均费用,且总体和关键亚组相对具有成本效果,但该结果存在相当大的统计不确定性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: High flow nasal cannula therapy (HFNC) and continuous positive airway pressure (CPAP) are two widely used modes of non-invasive respiratory support in paediatric critical care units. The FIRST-ABC randomised controlled trials (RCTs) evaluated the clinical and cost-effectiveness of HFNC compared with CPAP in two distinct critical care populations: acutely ill children ('step-up' RCT) and extubated children ('step-down' RCT). Clinical effectiveness findings (time to liberation from all forms of respiratory support) showed that HFNC was non-inferior to CPAP in the step-up RCT, but failed to meet non-inferiority criteria in the step-down RCT. This study evaluates the cost-effectiveness of HFNC versus CPAP.

METHODS: All-cause mortality, health-related Quality of Life (HrQoL), and costs up to six months were reported using FIRST-ABC RCTs data. HrQoL was measured with the age-appropriate Paediatric Quality of Life Generic Core Scales questionnaire and mapped onto the Child Health Utility 9D index score at six months. Quality-Adjusted Life Years (QALYs) were estimated by combining HrQoL with mortality. Costs at six months were calculated by measuring and valuing healthcare resources used in paediatric critical care units, general medical wards and wider health service. The cost-effectiveness analysis used regression methods to report the cost-effectiveness of HFNC versus CPAP at six months and summarised the uncertainties around the incremental cost-effectiveness results.

RESULTS: In both RCTs, the incremental QALYs at six months were similar between the randomised groups. The estimated incremental cost at six months was - £4565 (95% CI - £11,499 to £2368) and - £5702 (95% CI - £11,328 to - £75) for step-down and step-up RCT, respectively. The incremental net benefits of HFNC versus CPAP in step-down RCT and step-up RCT were £4388 (95% CI - £2551 to £11,327) and £5628 (95% CI - £8 to £11,264) respectively. The cost-effectiveness results were surrounded by considerable uncertainties. The results were similar across most pre-specified subgroups, and the base case results were robust to alternative assumptions.

CONCLUSIONS: HFNC compared to CPAP as non-invasive respiratory support for critically-ill children in paediatric critical care units reduces mean costs and is relatively cost-effective overall and for key subgroups, although there is considerable statistical uncertainty surrounding this result.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Sadique Z, Zapata SM, Grieve R, et al. Cost-effectiveness of high flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care. Crit Care. 2024. PMID: 39587649. doi:10.1186/s13054-024-05148-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。